Global David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights the latest trends and recommendations for business and corporate development transactions and capital financing of life sciences companies in 2022. We are currently experiencing economic headwinds, making it a challenging time for growth companies such as…
Europe Sparks, the Swiss Exchange’s newly launched small and medium sized enterprise (SME) trading venue, intends to make it easier for biotech SMEs to raise capital and strengthen their profile. The Swiss biotech sector has proven to be attractive for investors, with venture capital investments rising almost steadily over the past…
Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…
Europe The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly beyond COVID-19. According to the Swiss Biotech Report presented at the Swiss Biotech Day 2022 in Basel, the sector experienced…
China As China struggles to maintain its ‘dynamic zero-COVID’ policy in the face of Omicron variant outbreaks, other key talking points emerging from the world’s second-largest healthcare and life sciences market include Chinese firms’ deals to manufacture generic versions of Pfizer’s COVID antiviral, Kintor’s 229 percent share price leap after positive…
Spain AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to reevaluate public funding mechanisms at a national and European level, and provides an explanation for Spain’s leadership in clinical trials…
Europe A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’ shuttering of its US R&D footprint. BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029:…
Spain Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is set to become a hub for advanced therapies and personalized medicine. In addition, the CEO boasts about Cataolina being at…
Spain Alta Life Sciences is one of Catalonia’s top venture capital investor groups in the biotech sector. Montserrat Vendrell, partner and a pivotal figure in the development of the region’s life sciences ecosystem, explains the VC’s investment strategy, their connection with US-based funds, and the challenges ahead for Catalonia’s bioregion. …
Hong Kong Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and healthcare companies in 2021. “[Last year’s listings] made us rank first by number of deals and second by the amount…
Spain VIVEbiotech is a Spanish CDMO specialised in the production of lentiviral vectors used in gene therapy. Its CEO, Dr Gurutz Linazasoro, tells the story of the company’s creation, comments on the unique properties of lentiviral vectors, and analyses the main trends shaping the future of the gene therapy industry. In…
Global Based on analysis from Crunchbase, read on for 2021’s largest VC investments into the biotech industry (which topped USD 65 billion last year) and 2021’s busiest biotech lead investors overall. Made with Visme Infographic Maker Made with Visme Infographic Maker
See our Cookie Privacy Policy Here
